Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Maciej Tatarczuch, Colm Keane, Christina Brown, Pratyush Giri, Gavin Cull, Masa Lasica, Charles Shuttleworth, Joel Wight, Marjan Tabesh, Belinda E Butcher, Sze Ting Lee, Eliza A. Hawkes, Gareth P. Gregory

Blood (2024) 144 (Supplement 1): 4502.2.

https://doi.org/10.1182/blood-2024-200410

Published: 2024

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Chan Y. Cheah, Amanda Jane Johnston, Joel Wight, Piers Blombery, Katharine L. Lewis, Rory Bennett, Jing Xie, Stella Vlahos, Joyce Gonzales, Sally Binks, John F. Seymour

Blood (2024) 144 (Supplement 1): 4410.

https://doi.org/10.1182/blood-2024-199108

Published: 2024

Journal Articles

Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma

Rakin Chowdhury, Kate Manos, Melinda Burgess, Geoffrey Chong, Sze-Ting Lee, Zachary Hawula, Nella Tuczko, Charmaine Smith, Tineke Fancourt, Leonid Churilov, Andrew Scott, Allison Barraclough, Joel Wight, Joe McKendrick, Wendi Lin, Fiona Swain, Eliza A. Hawkes, Colm Keane

Blood (2024) 144 (Supplement 1): 6213.

https://doi.org/10.1182/blood-2024-201230

Published: 2024

Journal Articles

Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

Fiona Swain, Melinda Burgess, Sarah Kempe, Muhammed B. Sabdia, Andrea S Henden, Joel Wight, Eliza A. Hawkes, Howard Mutsando, Dipti Talaulikar, Lilia Merida de Long, Simone Birch, Penelope Wyche, Zachary Hawula, Rakin Chowdhury, Maher K. Gandhi, Colm Keane

Blood (2024) 144 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2024-199352

Published: 2024

Journal Articles

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Blood (2023) 142 (Supplement 1): 735.

https://doi.org/10.1182/blood-2023-178403

Published: 2023

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax in Patients with Treatment-Naïve Advanced-Stage Follicular Lymphoma: First Results of the Investigator-Initiated Phase Ib/II, Multicenter Leverage Study

Chan Y. Cheah, Katharine L. Lewis, Rory Bennett, Amanda Jane Johnston, Joel Wight, Jing Xie, Stella Vlahos, Katrina Celeste, Sally Binks, John F. Seymour

Blood (2023) 142 (Supplement 1): 1659.

https://doi.org/10.1182/blood-2023-184660

Published: 2023

Journal Articles

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Lynette C.Y. Chee, David M Ross, Shuh Ying Tan, Joel Wight, George Kannourakis, Miranda Ross, Wei Feng, Ying Jiang, Harveen Dhillon Natarajan, Christine Graham, Christopher Rovaldi, Simon Cooper, Jen L. Salstrom

Blood (2022) 140 (Supplement 1): 8181–8183.

https://doi.org/10.1182/blood-2022-166578

Published: 2022

Journal Articles

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

Blood (2021) 138 (Supplement 1): 2532.

https://doi.org/10.1182/blood-2021-145959

Published: 2021

Journal Articles

A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone, cytarabine, oxaliplatin) and Autologous Stem Cell Transplant (ASCT) in Fit Mantle Cell Lymphoma (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial

Eliza Hawkes, Shivam Agrawal, Sze-Ting Lee, Joel Wight, Greg Hapgood, Tasman Armytage, Nicole Wong Doo, Tara Cochrane, Chan-Yoon Cheah, Ian Bilmon, Matthew Ku, Stephen Opat, Bianca Devitt, Chun Yew Fong, Tineke Fancourt, Mannu Walia, Gloria Nkhoma, Allison Barraclough

Blood (2021) 138 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2021-149308

Published: 2021

Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2021-147335

Published: 2021

Journal Articles

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, MBBS, Masa Lasica, MD, Andrew Grigg, MBBS, MD FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Jonathan Wong, MBBS, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Gareth P. Gregory, Shane A Gangatharan, MBBS, FRACP, FRCPA, Tara Cochrane, MBBS,FRCPA,FRACP, Kristen Piper, Leonid Churilov, Eliza A Hawkes, FRACP,MDMBBS

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-138642

Published: 2020

Journal Articles

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Eliza A Hawkes, FRACP,MDMBBS, Geoffrey Chong, MD, Charmaine Smith, Sze-Ting Lee, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, MBBS, Niles Elizabeth Nelson, BSc, MBBS, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, MBBS, MD FRACP, FRCPA, Colm Keane, MD, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Kate Manos, MBBS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136024

Published: 2020

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship

Georgina L Ryland, PhD, Lucy C Fox, MBBS FRACP FRCPA, Ella Thompson, PhD, Graham John Lieschke, PhD MBBS, FRACP, David Hughes, MD MRCP, Francoise Marie Mechinaud, MD FRACP, Anthea Louise Greenway, MBBS, Janine Campbell, MBBS, Erica M Wood, MBBS FRACP FRCPA, Jennifer Lickiss, PhD, Joel Wight, MBBS FRACP FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Alison Trainer, MBBS, Elly Lynch, Melissa Martyn, Clara Gaff, David Ritchie, MBChB, PhD FRACP, FRCPA, Piers Blombery, MBBS

Blood (2018) 132 (Supplement 1): 3867.

https://doi.org/10.1182/blood-2018-99-114410

Published: 2018

Journal Articles

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Joel Wight, MBBS, Kathryn Jackson, MBBS, Ashanka Mahilal Beligaswatte, BA, MBBS, MD FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA, Louisa Martin, MBBS, Ian D. Lewis, MBBS PhD FRACP FRCPA, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Daniela Zantomio, FRACP, FRCPA, MBBS, Simon Z. He, MBBS,FRACP,FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Kirk Morris, FRACP FRCPA MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS

Blood (2016) 128 (22): 3989.

https://doi.org/10.1182/blood.V128.22.3989.3989

Published: 2016

Journal Articles

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Ashvind A Prabahran, MBBS, Mark Tacey, BSc, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Danielle Strong, Andrew Wei, MBBS, PhD, Courtney Tate, MBBS, Paula Marlton, MBBS, Joel Wight, MBBS, Andrew Grigg, MBBS, MD FRACP, FRACPA, Annabel Tuckfield, MBBS, FRACP, FRCPA, PhD, Jeff Szer, MB, BS, FRACP, David S. Ritchie, MDPhD, Lynette C.Y. Chee, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2599.

https://doi.org/10.1182/blood.V126.23.2599.2599

Published: 2015

NARROW

Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress

Obinutuzumab, Lenalidomide and Venetoclax for the Initial Treatment of Patients with Advanced-Stage Follicular Lymphoma: Primary Analysis of an Investigator-Initiated Phase Ib/II, Multicenter Study (LEVERAGE)

Biological Features of Response to Immune Checkpoint Inhibitor and Rituximab Priming in Diffuse Large B-Cell Lymphoma

Multiomics Analysis of Paired Diagnosis and Relapse DLBCL Biopsies Shows a Reduction in T Cell Infiltration and Function at Relapse

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naïve Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 ‘Wamm’ Trial

Obinutuzumab, Lenalidomide and Venetoclax in Patients with Treatment-Naïve Advanced-Stage Follicular Lymphoma: First Results of the Investigator-Initiated Phase Ib/II, Multicenter Leverage Study

Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA)

A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone, cytarabine, oxaliplatin) and Autologous Stem Cell Transplant (ASCT) in Fit Mantle Cell Lymphoma (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Providing Diagnoses in Bone Marrow Failure Syndromes through Multimodal Comprehensive Genomic Evaluation and Multidisciplinary Care: The Melbourne Genomics Health Alliance Bone Marrow Failure Flagship

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only